Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes
- Registration Number
- NCT02540707
- Lead Sponsor
- National Taiwan University Hospital
- Brief Summary
Background/Purpose: The overactive bladder syndrome (OAB) affects around 17 % of female population. Antimuscarinics can affect autonomic system, arterial stiffness and psychosomatic distress. However, there is no such research for the new drug- mirabegron (a β3-agonist). Thus, the aim of our study is to analyze the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups.
Patients and Methods: The investigators will perform a prospective randomized controlled study to recruit 150 female OAB patients at the outpatient clinic of Department of Obstetrics and Gynecology of National Taiwan University Hospital. All OAB female patients will be asked to complete Urgency Severity Scales, Overactive Bladder Symptoms Scores questionnaires, King's Health questionnaires, UDI-6 \& IIQ-7, Patient Health Questionnaire, brief symptom rating scale (BSRS), Maudsley personality inventory (MPI) and adaptability, partnership, growth, affection, and resolve (APGAR) questionnaires, Sleep and Dietary habit Questionnaire, standard 12-leads electrocardiography (ECG), 5 minutes Holter monitoring, cardio-ankle vascular index (CAVI) test, bladder diary, 20-min pad test, urodynamic studies and measurement of urinary nerve growth factors level before and after 12 weeks' mirabegron versus solifenacin treatment. STATA software is used for statistical analyses.
Possible Results: The investigators can answer that the between-group differences in heart rate variability, cardio-ankle vascular index, ankle-brachial pressure index, psychosomatic distress, personality trait, family support and clinical outcomes between the mirabegron and the solifenacin groups. The above conclusions should be important for pre-treatment consultation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 113
- Women with overactive bladder syndrome
- ≥20 year-old
- Urine retention,
- acute angle glaucoma,
- myasthenia gravis,
- ulcerative colitis,
- megacolon
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Solifenacin solifenacin Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd \* 12 weeks Mirabegron mirabegron Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd \* 12 weeks
- Primary Outcome Measures
Name Time Method Between-group difference of the effect of drug on heart rate variability 12 weeks Between-group difference of the effect of drug on heart rate variability, such as low frequency and high frequency
Between-group difference of the effect of drug on psychosomatic distress 12 weeks Between-group difference of the effect of drug on psychosomatic distress by Brief Symptom Rating Scale
- Secondary Outcome Measures
Name Time Method Between-group difference of the effect of drug on arterial stiffness 12 weeks Between-group difference of the effect of drug on arterial stiffness by cardio-ankle vascular index
Between-group difference of the effect of drug on clinical efficacy 12 weeks Between-group difference of the effect of drug on clinical efficacy by Overactive Bladder Symptoms Score Questionnaire
Trial Locations
- Locations (1)
Outpatient clinics, Department of Obs/Gyn, National Taiwan University Hospital
🇨🇳Taipei, Taiwan